Logo

American Heart Association

  2
  0


Final ID: 4146727

Intensive lifestyle intervention, cardiac biomarkers and atherosclerotic cardiovascular disease in type 2 diabetes and overweight or obesity – a post-hoc analysis of the Look Action for Health in Diabetes (AHEAD) trial

Abstract Body (Do not enter title and authors here): Introduction: High-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with atherosclerotic cardiovascular disease (ASCVD) risk in type 2 diabetes (T2D). However, the association of longitudinal changes in these cardiac biomarkers with ASCVD risk in T2D is not well-established. Furthermore, the effects of an intensive lifestyle intervention (ILI) targeting weight loss on cardiac biomarkers is not well-characterized.
Methods: Participants of the Look AHEAD (Action for Health in Diabetes) trial with T2D and overweight or obesity were included. Hs-cTnT and NT-proBNP were measured at baseline, 1- and 4-year follow-up (Roche Diagnostics). Adjusted Cox models were created to evaluate the associations of baseline, 1-, and 4-year change in cardiac biomarkers with ASCVD risk (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina). The effects of the ILI targeting weight loss versus diabetes support and education (DSE) on cardiac biomarker changes were summarized as the geometric mean ratio (GMR) and 95% confidence interval (CI).
Results: Among 3,984 participants with available cardiac biomarker data, there were 771 ASCVD events (median follow-up: 12 years). Higher hs-cTnT and NT-proBNP at baseline were each significantly associated with higher ASCVD risk (Figure 1A). Changes in hs-cTnT and NT-proBNP over 1-year follow-up were not significantly associated with ASCVD risk. However, sustained increases in hs-cTnT and NT-proBNP over 4-year follow-up were each significantly associated with higher ASCVD risk. The ILI versus DSE was significantly associated with lower hs-cTnT at 1- and 4-year follow-up (GMR [95% CI]: 0.96 [0.93-0.99] and 0.94 [0.92-0.97]), respectively) (Figure 1B). In contrast, NT-proBNP increased with the ILI (vs. DSE) at 1-year (GMR [95% CI]: 1.11 [1.05-1.17]), but this difference was attenuated and no longer significant at 4-years.
Conclusions: Among adults with T2D, sustained increases in hs-cTnT and NT-proBNP over 4-year follow-up were associated with higher ASCVD risk. An ILI targeting weight loss led to a significant reduction in hs-cTnT and transient rise in NT-proBNP that attenuated over time.
  • Patel, Kershaw  ( Houston Methodist , Houston , Texas , United States )
  • Bertoni, Alain  ( WAKE FOREST UNIV SCHOOL MED , Pfafftown , North Carolina , United States )
  • Espeland, Mark  ( Wake Forest School of Medicine , Winston-Salem , North Carolina , United States )
  • Pandey, Ambarish  ( UTSW MEDICAL CENTER , Dallas , Texas , United States )
  • Chunawala, Zainali  ( University of Texas Southwestern , Dallas , Texas , United States )
  • Segar, Matthew  ( Texas Heart Institute , Houston , Texas , United States )
  • Garcia, Katelyn  ( Wake Forest School of Medicine , Winston-Salem , North Carolina , United States )
  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Wang, Thomas  ( UT SOUTHWESTERN MEDICAL CENTER , Dallas , Texas , United States )
  • Januzzi, James  ( Massachusetts General Hospital , Wellesley Hills , Massachusetts , United States )
  • Butler, Javed  ( Baylor Scott and White Research Institute , Dallas , Texas , United States )
  • Lam, Carolyn  ( National Heart Centre Singapore, Duke-National University of Singapore , Singapore , Singapore )
  • Author Disclosures:
    Kershaw Patel: DO have relevant financial relationships ; Consultant:Novo Nordisk:Active (exists now) | Alain Bertoni: DO NOT have relevant financial relationships | Mark Espeland: DO NOT have relevant financial relationships | Ambarish Pandey: DO have relevant financial relationships ; Consultant:Tricog:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Semler:Active (exists now) ; Consultant:Science37:Active (exists now) ; Research Funding (PI or named investigator):SCPharma:Active (exists now) ; Advisor:Medtronic:Active (exists now) ; Advisor:Axon:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Research Funding (PI or named investigator):Ultromics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Roche:Active (exists now) | Zainali Chunawala: DO NOT have relevant financial relationships | Matthew Segar: DO have relevant financial relationships ; Executive Role:descendantsDNA:Active (exists now) ; Executive Role:ReCODE Medical:Active (exists now) | Katelyn Garcia: DO NOT have relevant financial relationships | Chiadi Ndumele: DO NOT have relevant financial relationships | Thomas Wang: DO NOT have relevant financial relationships | James Januzzi: DO have relevant financial relationships ; Researcher:Abbott:Active (exists now) ; Consultant:Prevencio:Active (exists now) ; Consultant:Quidel:Active (exists now) ; Consultant:Roche Diagnostics:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Beckman:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Jana Care:Active (exists now) ; Individual Stocks/Stock Options:Imbria:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Applied Therapeutics:Active (exists now) ; Researcher:BMS:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) | Javed Butler: No Answer | Carolyn Lam: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:
More abstracts on this topic:
A Meta-analysis of Folic Acid Supplementation Efficacy in Cardiovascular Diseases Prevention.

Calderon Martinez Ernesto, Camacho Davila Karen Fabiola, Pinto-colmenarez Rafael, Arruarana Victor, Arvelaez Pascucci Joanne, Castillo Jaqueline Livier, Alonso Ramirez Angie Carolina, Ghattas Patricia, Giron De Marza Maria, Sosaya Zuñiga Briggitte Solange, Martinez Lilan Jonathan David, Paredes Romero Enrique

An Emerging Epidemic: Obesity Related High Output Heart Failure

Singh Pooja, Wondmagegn Admasu, Lam Phillip

More abstracts from these authors:
Cardiac biomarkers, intensive lifestyle intervention, and risk of heart failure subtypes in type 2 diabetes – a post-hoc analysis of the Look AHEAD trial

Chunawala Zainali, Bertoni Alain, Espeland Mark, Pandey Ambarish, Patel Kershaw, Segar Matthew, Garcia Katelyn, Bhatt Deepak, Wang Thomas, Januzzi James, Butler Javed, Lam Carolyn

Preventing Stage C Begins with Stage B

Patel Kershaw, Ndumele Chiadi

You have to be authorized to contact abstract author. Please, Login
Not Available